Central America Pharmaceuticals and Healthcare Report Q3 2014

  • May 2014
  • -
  • Business Monitor International
  • -
  • 68 pages

Includes 3 FREE quarterly updates

BMI View:

Panama and Costa Rica will continue to outperform in comparison with other Central
American countries, namely El Salvador, Guatemala, Honduras, Nicaragua and Belize. Improving healthcare investment present revenue-generating opportunities for multinational pharmaceutical companies. Generic drugmakers can also benefit from the widespread uptake of generic drugs in the region and its efficient purchasing platforms, such as COMISCA.

Headline Expenditure Projections

- Pharmaceuticals: US$3.7bn in 2013 to US$3.9bn in 2014; +4.7%. Our forecast has been revised slightly up since Q214 due to more promising industry data.
- Healthcare: US$16.6bn in 2013 to US$17.5bn in 2014; +5.4 %. Our forecast has been revised downwards since Q214 due to less optimistic macroeconomic data.
Risk/Reward Ratings: Based on our analysis and assessment of the market's appeal to pharmaceutical companies in our Q314 Pharmaceutical Risk/Reward Ratings (RRRs), the Americas scores 49 out of 100, below the Western Europe region (67), Central and Eastern Europe (52), and Asia Pacific (52), but above the Middle East and Africa (42) region. Of the seven Central American countries surveyed, at 40.9 Panama's RRR score ranks first, followed by Costa Rica (37.6), Guatemala (34.3), Honduras (34.2), Belize
(32.4), El Salvador (32.0) and Nicaragua (29.8).

Table Of Contents

Central America Pharmaceuticals and Healthcare Report Q3 2014
BMI Industry View 7
SWOT 9
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Central America Minus Mexico Pharmaceutical Sales, Historic Data And Forecasts 11
Guatemala 11
Table: Guatemala Pharmaceutical Sales Forecasts 12
Costa Rica 12
Table: Costa Rica Pharmaceutical Sales Forecasts 13
El Salvador 13
Table: El Salvador Pharmaceutical Sales Forecasts 14
Honduras 14
Table: Honduras Pharmaceutical Sales Forecasts 15
Panama 15
Table: Panama Pharmaceutical Sales Forecasts 15
Nicaragua 16
Table: Nicaragua Pharmaceutical Sales Forecasts 16
Belize 17
Table: Belize Pharmaceutical Sales Forecasts 17
Healthcare Market Forecast 18
Table: Central America Minus Mexico Healthcare Expenditure Trends, Historical Data and Forecasts . 19
Guatemala 19
Table: Guatemala Healthcare Expenditure Forecasts 19
Costa Rica 19
Table: Costa Rica Healthcare Expenditure Forecasts 20
El Salvador 20
Table: El Salvador Healthcare Expenditure Forecasts 22
Panama 22
Table: Panama Healthcare Expenditure Forecasts 23
Honduras 23
Table: Honduras Healthcare Expenditure Forecasts 24
Nicaragua 24
Table: Nicaragua Healthcare Expenditure Forecasts 24
Belize 25
Table: Belize Healthcare Expenditure Forecasts 25
Pharmaceutical Trade Forecast 26
Guatemala 27
Table: Guatemala Pharmaceutical Trade Data And Forecasts (USDmn) 28
Costa Rica 28
Table: Costa Rica Pharmaceutical Trade Data And Forecasts (USDmn) 28
El Salvador 29
Table: El Salvador Pharmaceutical Trade Data And Forecasts (USDmn) 29
Panama 29
Table: Panama Pharmaceutical Trade Data And Forecasts (USDmn) 30
Honduras 30
Table: Honduras Pharmaceutical Trade Data And Forecasts (USDmn) 30
Nicaragua 31
Table: Nicaragua Pharmaceutical Trade Data And Forecasts (USDmn) 31
Belize 31
Industry Risk Reward Ratings 32
Americas Risk/Reward Ratings 32
Central America Risk/Reward Ratings 38
Industry Trends And Developments 39
Regional Developments 39
Guatemala 41
Costa Rica 42
El Salvador 46
Panama 48
Honduras 48
Nicaragua 50
Belize 51
Epidemiology 52
Clinical Trials 53
Regulatory Development 56
Intellectual Property Regime 56
Costa Rica 57
El Salvador 58
Honduras 58
Nicaragua 59
Panama 59
Guatemala 59
Competitive Landscape 60
Company Profile 61
Ancalmo Internacional 61
Donovan Werke 63
Glossary 65
Methodology 67
Pharmaceutical Expenditure Forecast Model 67
Healthcare Expenditure Forecast Model 67
Notes On Methodology 68

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • November 2014
  • by Global Data

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the ...

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023

  • $ 7 995
  • Industry report
  • November 2014
  • by Global Data

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023 Summary There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.